Learn, Analyse & Invest
only with
only with
+91
Download Orca
Eiko Lifesciences Ltd.
Eiko Lifesciences
₹ 0.00
0.00 (0.00)%
NSE
BSE
Chemicals
Small-cap - With a market cap of ₹72.25 Cr.
| EX-Date | Purpose |
|---|---|
| 20 04 2021 | Audited Results |
| 30 07 2021 | Quarterly Results |
| 02 11 2021 | Quarterly Results |
| 08 02 2022 | Quarterly Results |
| 22 04 2022 | Quarterly Results |
| 12 08 2022 | Quarterly Results |
| 21 10 2022 | Quarterly Results |
| 17 01 2023 | Quarterly Results |
| 31 01 2023 | Inter alia, to approve the following matters:- 1. To consider and propose to increase in Authorised Share Capital of the Company and consequently alteration of Memorandum of Association of the company. 2. To consider the proposal for raising funds by way of issue of one or more instruments including equity shares, convertible or non-convertible securities of any description or warrants or debt securities, through preferential issue, private placements, right issue or any other methods or combination thereof as may be permitted under applicable laws, subject to such regulatory / statutory approvals as may be required, including the approval of the shareholders of the company. 3. Any other matter with the permission of the Chair.512441 Enbee Trade & Finance Ltd., 07/02/2023 Quarterly Results |
| 09 05 2023 | Audited Results |
| 15 05 2023 | Right Issue of Equity Shares |
| 30 06 2023 | Right Issue of Equity Shares |
| 11 07 2023 | Quarterly Results |
| 08 11 2023 | Quarterly Results |
| 14 12 2023 | Rights Issue Inter-alia and to approve the following matters; 1) Matter relating to payment of First and final call money on 55,44,178 partly paid-up equity shares of face value of Re. 10/- each which were issued and allotted on August 02, 2023 on right basis, pursuant to the Letter of Offer dated July 07, 2023. 2) Any other matter with the permission of the Chair |
| 08 02 2024 | Quarterly Results |
| 19 10 2024 | Quarterly Results |
| 25 11 2024 | Rights Issue |
| 12 02 2025 | Quarterly Results |
| 14 05 2025 | Audited Results & Quarterly Results |
| 31 10 2025 | Quarterly Results |
| 11 12 2025 | Inter alia, to consider the following: Proposal for raising of funds by way of issue of one or more of instruments comprising of Equity Shares, Convertible Securities of any other description or Warrants or Debt Securities, through Private Placement/Preferential Issue/Qualified Institutions Placement or such other methods or combinations thereof as may be decided by the Board and to approve ancillary actions for the above-mentioned fund raising, subject to such Statutory/Regulatory approvals as may be necessary, wherever required. |
| 29 01 2026 | Quarterly Results |
News
